RNA-seq of cardiomyocytes exposed to glucose deprivation with or without empagliflozin treatment
收藏Alliance of Genome Resources2026-08-01 收录
官方服务：
资源简介：
Glucose-lowering drugs sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of serious heart failure events, regardless of diabetes status, but the underling mechanism of this cardioprotective benefit is unknown. Here, we performed RNA-seq screening in cardiomyocytes to determine the potential cardioprotective mechanism of empagliflozin (EMPA).
